Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Jiangsu T-mab BioPharma
- 21 Aug 2017 Planned initiation date changed from 12 Aug 2017 to 1 Sep 2017.
- 10 Aug 2017 New trial record